豬肉板塊拉昇走強 全國生豬生產繼續向好
格隆匯4月22日丨豬肉板塊拉昇走強,禾豐牧業逼近漲停,傲農生物漲超6%,天康生物漲超5%,新五豐、唐人神等紛紛跟漲。從農業農村部獲悉,3月份生豬產銷秩序基本恢復,全國生豬生產繼續向好,主要生產指標好於2月份,豬肉市場價格連續8週迴落。據對全國400個定點監測縣數據彙總,3月份能繁母豬存欄環比增長2.8%,快於1月份的1.2%和2月份的1.7%,連續6個月增長。全國有28個省份能繁母豬存欄環比增長,比上月增加2個省份。其中,有10個省份能繁母豬存欄環比增幅超過4%。四川、湖南和河南等傳統養豬大省能繁母豬存欄分別連續4個月、5個月和7個月環比增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.